Literature DB >> 31232145

A Case of Serotonin Syndrome Caused by the Concomitant Utilization of Methylene Blue and Venlafaxine in an Oncological Patient.

Brian Gilbert1, Inyang E Akamune2.   

Abstract

Although the interaction between methylene blue and serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors is well documented, there remains a paucity of literature on identifying patient groups who may be at risk for experiencing this interaction. Here, we report a case of methylene blue and venlafaxine-induced serotonin syndrome in a patient with cancer.

Entities:  

Keywords:  adverse drug event; drug interaction; methylene blue; serotonin syndrome; venlafaxine

Mesh:

Substances:

Year:  2019        PMID: 31232145     DOI: 10.1177/0897190019850706

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  1 in total

1.  Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters.

Authors:  Katrina A Bramstedt
Journal:  Ther Innov Regul Sci       Date:  2020-10-01       Impact factor: 1.778

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.